ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer
20 July 2020 - 9:00PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Susan Altschuller, PhD has been appointed
Senior Vice President and Chief Financial Officer.
“Susan is an outstanding addition to our management team and we
are pleased to welcome her at this pivotal moment for ImmunoGen,
with the registration studies for our lead program enrolling, our
earlier-stage portfolio advancing, and a strong balance sheet,”
said Mark Enyedy, ImmunoGen’s President and Chief Executive
Officer. “Her energy and extensive experience in investor
relations, business planning, and corporate finance will be
invaluable as we enter the next stage of ImmunoGen’s evolution and
look to allocate our capital in the most effective and efficient
manner possible.”
Dr. Altschuller has 20 years of financial management, investor
relations, and business planning experience with leading
pharmaceutical and biotechnology companies. She joins ImmunoGen
from Alexion Pharmaceuticals where she started as Head of Investor
Relations before moving to Head of Enterprise Finance, where she
led global financial reporting and provided counsel on investment
prioritization to support the Company’s strategic imperatives.
Prior to joining Alexion, Dr. Altschuller was Head of Investor
Relations at Bioverativ, where she served as the primary interface
with Wall Street and led all investor-related activities for the
launch of the Biogen spin-off. Early in her career, Dr. Altschuller
held positions at Biogen in various functions of increasing
responsibility, including investor relations, corporate finance,
and commercial finance. She received a BSE in Biomedical
Engineering with Honors from Tulane University, a PhD in Biomedical
Engineering from the Illinois Institute of Technology, and an MBA
from the MIT Sloan School of Management.
“I am excited to be joining the ImmunoGen team and look forward
to playing a key role in the meaningful work the Company does to
deliver more good days for people living with cancer,” said Dr.
Altschuller. “The prospects and potential of its novel portfolio of
next generation antibody-drug conjugates is exciting, particularly
as the organization transitions from clinical-stage to a
fully-integrated commercial biotech.”
ABOUT IMMUNOGEN ImmunoGen is developing the next
generation of antibody-drug conjugates to improve outcomes for
cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
FORWARD LOOKING STATEMENTS This press release includes
forward-looking statements based on management's current
expectations. These statements include, but are not limited to,
ImmunoGen’s expectations related to the advancement of ImmunoGen’s
research and development programs and Dr. Altschuller’s potential
contributions to ImmunoGen. For these statements, ImmunoGen claims
the protection of the safe harbor for forward-looking statements
provided by the Private Securities Litigation Reform Act of 1995.
Various factors could cause ImmunoGen’s actual results to differ
materially from those discussed or implied in the forward-looking
statements, and you are cautioned not to place undue reliance on
these forward-looking statements, which are current only as of the
date of this release. Factors that could cause future results to
differ materially from such expectations include, but are not
limited to: the timing and outcome of ImmunoGen’s pre-clinical and
clinical development processes; the difficulties inherent in the
development of novel pharmaceuticals, including uncertainties as to
the timing, expense, and results of pre-clinical studies, clinical
trials, and regulatory processes; ImmunoGen’s ability to
financially support its product programs; risks and uncertainties
associated with the scale and duration of the COVID-19 pandemic and
resulting impact on ImmunoGen’s industry and business; and other
factors more fully described in ImmunoGen’s Annual Report on Form
10-K for the year ended December 31, 2019 and other reports filed
with the Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200720005141/en/
INVESTOR RELATIONS AND MEDIA ImmunoGen Courtney O’Konek
781-895-0600 courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From May 2023 to May 2024